Does Ozempic actually make you feel cold? Here's what we know

What did @realdrbae actually say?

The creator told their audience that hundreds of patients are reporting cold hands and feet after starting GLP-1 medications, and that patients believe the drug itself is causing the problem, not fat loss. Then came the key claim: "there is absolutely no evidence that these medications can lead to cold intolerance." They softened it slightly, saying they're "not saying these medications could not lead to cold intolerance," just that after 20 years of human use, the evidence is thin. It's a nuanced position, but the phrase "absolutely no evidence" is doing a lot of heavy lifting here, and that's where things get complicated.

The creator also identifies as an "appetite expert" receiving significant patient feedback, which suggests a clinical base of observation. That context matters when evaluating how they're framing anecdotal reports versus published evidence.

Does the science back this up?

Mostly, but not cleanly. The FDA prescribing information for semaglutide does not list cold intolerance or peripheral coldness as a known adverse effect. Large trials like the SUSTAIN and STEP programs did not identify it as a signal worth reporting. That much is accurate. But "absolutely no evidence" overstates the case.

There are plausible physiological mechanisms that have been studied. GLP-1 receptors are expressed in peripheral vasculature, and some preclinical research suggests GLP-1 agonism may affect vascular tone. A 2021 paper by Nystrom et al. in Cardiovascular Diabetology noted GLP-1 receptor activity in vascular smooth muscle, which could theoretically influence peripheral circulation. Separately, significant caloric restriction, which GLP-1 drugs strongly promote, is associated with reduced thermogenesis. Research by Reinhardt et al. (2015, Cell Metabolism) found that adaptive thermogenesis during caloric restriction can reduce core temperature and peripheral warmth. The creator dismisses the fat-loss explanation because patients say otherwise, but patient self-report is not a reliable way to separate direct drug effects from downstream metabolic effects.

What did they get wrong (or right)?

They got the broad strokes right. Cold intolerance is not a listed adverse effect, and there are no large controlled trials confirming it as a direct pharmacological consequence of GLP-1 receptor agonism. Credit where it's due: this is a creator resisting the urge to validate a popular complaint with bad science, which is rarer than it should be on TikTok.

What they got wrong is the framing. "Absolutely no evidence" is not accurate. There is limited mechanistic and observational evidence that deserves acknowledgment. There's also a methodological problem in dismissing the fat-loss explanation simply because patients deny it. Patients are not equipped to distinguish between a direct drug effect and a consequence of rapid caloric deficit and body composition change. A 2020 analysis by Sørensen et al. in Obesity Reviews documented cold sensitivity as a reported symptom during aggressive caloric restriction, independent of drug use. The creator presents a reasonable conclusion but reaches it through slightly sloppy reasoning.

What should you actually know?

If you are on a GLP-1 medication and your hands and feet are cold, there are a few things worth knowing. First, significant weight loss, particularly rapid loss of subcutaneous fat, is a well-documented cause of cold sensitivity. Fat is insulating tissue. Losing it quickly changes how your body manages heat at the periphery. Second, caloric restriction lowers basal metabolic rate and reduces thermogenesis, which makes people feel colder even without meaningful fat loss. Neither of these is a reason to stop the medication, but both are worth discussing with a prescriber.

Third, peripheral coldness that is new, asymmetric, or accompanied by color changes in fingers or toes warrants a clinical evaluation. Raynaud's phenomenon, thyroid changes, and anemia are all conditions that can emerge or worsen during weight loss and should not be attributed to GLP-1 medications without ruling out other causes. If symptoms are persistent or severe, a conversation with your provider is the right move, not a TikTok comment section.

Bottom line on this video

This is a better-than-average medical TikTok. The creator avoids the trap of confirming a popular complaint to drive engagement, and their bottom line, that direct evidence for GLP-1-induced cold intolerance is weak, is defensible. The "absolutely no evidence" phrasing is imprecise and could mislead viewers into dismissing a symptom that may have real, addressable causes. The video would have been stronger with a brief explanation of why rapid caloric restriction and fat loss independently cause cold sensitivity, since that's probably what most of those DMs are actually describing.